Cardiotonic Agents/pharmacology; Cardiotonic Agents/therapeutic use; Heart Failure/prevention & control; Hypertrophy, Left Ventricular/drug therapy; Receptors, G-Protein-Coupled/antagonists & inhibitors; Sulfonamides/pharmacology; Sulfonamides/therapeutic use; Animals; Animals, Newborn; Cardiomegaly/metabolism; Cardiomegaly/prevention & control; Cardiotonic Agents/blood; Cardiotonic Agents/pharmacokinetics; Cells, Cultured; Disease Models, Animal; Disease Progression; Drug Evaluation, Preclinical; Fibroblasts/drug effects; Fibrosis/prevention & control; Heart/drug effects; Heart/physiopathology; Heart Failure/mortality; Heart Failure/physiopathology; Hypertrophy, Left Ventricular/metabolism; Hypertrophy, Left Ventricular/physiopathology; Male; Myocardial Infarction/drug therapy; Myocardial Infarction/metabolism; Myocardium/cytology; Myocardium/metabolism; Myocardium/pathology; Random Allocation; Rats; Rats, Sprague-Dawley; Sulfonamides/blood; Sulfonamides/pharmacokinetics; Up-Regulation/drug effects; Urotensins/antagonists & inhibitors; Urotensins/metabolism